COVID-19
-
RSV hospitalization increases cardiorespiratory event, COPD exacerbation risk
Caihua Liang, MD, PhD, and Elizabeth Begier, MD, discuss the importance of prevention in light of data showing elevated risk for up to 180 days following the acute infection.
-
Study shows glucocorticoids cut mortality in community acquired pneumonia in low-income settings
Anthony O. Etyang, MBChB, MMed, MSc, PhD, said recent data bolster the evidence that steroids may be useful for severe pneumonia in high-income settings as well.
-
Trials suggest RSV vaccine reduces hospitalization for cardiorespiratory conditions in older adults
Data from studies in the United States and Denmark add to the growing evidence that respiratory syncytial virus (RSV) vaccination is effective in older adults.
-
Session to review latest science, recommendations for vaccines against respiratory infections
Charles Dela Cruz, MD, PhD, will chair a Sunday afternoon session on current practice recommendations for COVID-19, influenza, RSV, and pneumococcal vaccines.
-
Azelastine nasal spray shows promise in preventing SARS-CoV-2 infections
Researcher Robert Bals, MD, PhD, said this is a starting point, a signal of efficacy that warrants confirmation in larger, multicentric, phase 3 trials.
-
COVID-19 immune patterns offer hope for future IPF treatment
Jose D. Herazo-Maya, MD, and colleagues are investigating a mechanism of T-cell suppression that may contribute to the development of a treatment for pulmonary fibrosis.
-
Mitigating risk of asthma emergencies during respiratory season
During flu season, asthma emergencies become a heightened concern, especially among children. Proactive measures including vaccination, updated asthma action plans, and access to quick relief medications are critical.
